波士頓，2013年4月9日，美通社-生物IT世界報導：Accelrys公司(納斯達克: ACCL)—— 一個科技創新生命周期管理軟件領域的領導者于今天宣布，基于云計算的信息管理和協同工作平臺Accelrys HEOS®目前要與BT攜手成為應用于生命科學研發領域的云端計算平臺。BT為生命科學研發領域的HEOS用戶提供安全的、可靠的和可伸縮的云環境，這使得醫藥研究機構及其合作伙伴之間的網絡協作更加富有成效。BT和Accelrys之間的這一盟約在增強Accelrys外部化協作套件的企業級能力的同時，也推動了主體公司和外部化公司之間的聯系，自2012年4月開始，公司之間的聯系就已經開始。配備由BT提供的企業云基礎設施后，Accelrys外部化協作套件就能夠滿足研究機構需要過渡到一個外部網絡研究環境中的需求。
“隨著制藥行業迅速向網絡研究模式轉變，相關組織機構正在努力提供安全、實時的信息交換和橫跨外部網絡的知識產權保護，”Accelrys公司高級副總裁兼首席技術官Matt Hahn博士說，“當他們向這種新的模式轉變時，Accelrys和BT共同認識到藥物研發機構需要在一個安全、可靠、全球化的云基礎設施中進行高效的合作。”
“由于現今需要通過外部網絡研究來滿足關鍵業務問題，因此BT在生命科學研發中的強健的云服務就顯得至關重要，”BT全球服務部制藥和化工領域總裁Bas Burger說，“Accelrys HEOS同其它用于外部化研究的Accelrys應用軟件結合起來成為BT生命科學研發中的一部分，這樣可使工作在制藥和生物技術公 司，以及學術界和政府科研的科學家們都能夠在云環境中高效協作。此平臺旨在讓客戶遵循該行業嚴格的安全、監管和合規要求。”
作為Accelrys外部化協作套件的一部分，Accelrys HEOS證明了軟件即服務(SaaS)工作平臺可加速協同合作的藥物發現。該系統提供安全、實時的云端數據訪問，可訪問的數據包括化學品注冊、生物測定結果、計算和可視化分析、安全評估和藥代動力學數據以及其他項目信息，這將大幅降低訪問這些材料信息所付出的努力和IT費用。由于所有知識產權都存儲在一個安全的、包含具體項目信息的信息倉庫內，因此Accelrys HEOS能幫助制藥和生物技術公司、合同研究機構、學術機構以及其他有合作關系的研究組織訪問關鍵信息、分享結果并及時地做出正確決策。
應用于生命科學研發領域的BT使用BT云計算技術已經開發出一個安全的、被隔離的平臺。它允許科學家在silico工作流和數據管道中進行構造和編排，以便識別新藥物靶點和候選藥物。該平臺，開始于2012年的BioIT World，，它使科學家們能夠創建全球化的項目組，并且使他們可以通過社交媒體工具進行協作。該生態系統允許科學家們安全地上傳文件、共享結果并通過IM進行交流，包括語音、視頻或者聊天。他們還可以在一個環境中分析結果，這個環境可以分割數據，并可以使用合格的硬件組件和制藥行業特定的工作流。
如想獲取更多有關Accelrys HEOS和Accelrys Externalized Collaboration Suite的信息，請訪問Accelrys公司官方網站。
關于Accelrys
Accelrys公司(NASDAQ: ACCL)，是系統提供科技創新生命周期管理軟件領域的領導者，支持行業和組織依靠科技創新來提升自身競爭力。行業領先的Accelrys企業平臺，提供廣泛而靈活的科學解決方案，優化整合科學的多樣性、實驗過程以及在研發、生產、工藝放大早期生產階段產品開發過程的信息需求。通過在建模與仿真、企業級實驗室管理、工作流和自動化方面的應用程序、數據管理及信息學方面的整合能力，Accelrys使得科學創新者以前所未有的方式訪問、組織、分析并分享，最終提高創新能力，提高生產率和合規性，降低成本并加速從實驗室到市場的時間。
Accelrys解決方案應用于1300多家公司，涉及制藥、生物技術、能源、化學、航空航天、快速消費品和工業產品等行業。Accelrys總部位于美國加利福尼亞州圣迭戈，員工包括200多名具有博士學位的科學家。如想了解更多關于Accelrys的公司的信息，您可以訪問公司網站 www.accelrys.com。
關于BT
BT是世界領先的通信服務和解決方案供應商之一，客戶遍布170多個國家，其主要業務包括：提供全球網絡IT服務;提供地方、國家及國際電信服務，滿足在家中、工作中以及在移動的用戶的使用需要;提供寬帶、互聯網產品與服務，以及聚集固定/移動的產品與服務。BT主要包括四個業務部門：BT全球服務部、BT零售部、BT批發部和Openreach。
2013年3月31日的財年會議上公布了BT集團的總收入為£18,897m，稅前利潤為£2,445m。英國電信公司(BT)是英國電信集團(BT Group)全資子公司，幾乎包括BT集團的所有業務和資產。英國電信集團已分別在倫敦和紐約的證券交易所上市。如想了解更多相關信息，您可以訪問BT公司網站www.btplc.com。
附英文原文
Accelrys HEOS® Goes Live on BT Cloud Environment
Industry-leading research collaboration workspace within Accelrys Externalized Collaboration Suite moves to secure, reliable, scalable cloud infrastructure
BOSTON, April 9, 2013 /PRNewswire/ -- Bio-IT World -- Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, today announced that the cloud-based Accelrys HEOS® information management and collaboration workspace is now live on BT for Life Sciences R&D cloud platform. BT for Life Sciences R&D provides a secure, reliable and scalable cloud environment for HEOS users, enabling more efficient and productive networked collaboration by pharmaceutical research organizations and their partners. The latest engagement between BT and Accelrys furthers the relationship on hosting and externalization that has been in place between the companies since April 2012, while strengthening the enterprise capabilities of the Accelrys Externalized Collaboration Suite announced today at Bio-IT World. Combined with the enterprise cloud infrastructure provided by BT, the Accelrys Externalized Collaboration Suite addresses the needs of research organizations transitioning to an externalized network research environment.
"With the pharmaceutical industry moving rapidly to a network research model, organizations are struggling to provide secure, real-time information exchange and IP protection across externalized networks," said Dr. Matt Hahn, senior vice president and chief technology officer, Accelrys. "Accelrys and BT recognize the need for drug discovery research organizations to collaborate effectively within a secure, reliable, global cloud infrastructure as they move to this new model."
"BTs robust Life Sciences for R&D cloud service is essential to meeting the critical business issues raised by externalized network research today," said Bas Burger , president of Global Pharmaceutical & Chemical for BT Global Services. "Combining Accelrys HEOS and other Accelrys applications for externalized research as part of BT for Life Sciences R&D enables scientists working in pharmaceutical and biotechnology companies, as well as academia and government, to collaborate effectively in a cloud environment. The platform is designed to allow customers to comply with the industrys stringent security, regulatory and compliance requirements."
As part of the Accelrys Externalized Collaboration Suite, Accelrys HEOS is a proven Software-as-a-Service (SaaS) workspace that accelerates collaborative drug discovery. The system provides secure, real-time cloud access to data about such things as chemical registration, biological assay results, computational and visual analytics, safety assessment and pharmacokinetics data, and other project information. This material can be accessed with greatly reduced effort and IT overhead. Accelrys HEOS enables pharmaceutical and biotechnology companies, contract research organizations, academic institutions and other partnering research organizations to access critical information, share results and make informed decisions in a timely manner with all IP stored in a secure, project-specific information warehouse.
BT for Life Sciences R&D was developed as a secure and segregated platform, using BT Cloud Compute. It allows scientists to construct and orchestrate in silico workflows and data pipelines so that new pharmaceutical targets and drug candidates can be identified. This platform, launched at BioIT World 2012, enables research scientists to create global project groups and collaborate using social media tools. This ecosystem allows them to securely upload documents, share results and communicate via IM, voice, video or chat. They can also analyze results in an environment that segments data and uses qualified hardware components and workflows specific to the pharmaceutical industry.
Refer to the Accelrys website for more information on Accelrys HEOS and the Accelrys Externalized Collaboration Suite.
About Accelrys, Inc.
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad and flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and early manufacturing phases of product development. By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow and automation, and data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market.
Accelrys solutions are used by more than 1,300 companies in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries. Headquartered in San Diego, California, USA, Accelrys employs more than 200 full-time PhD scientists. For more information about Accelrys, visit www.accelrys.com.
About BT
BT is one of the worlds leading providers of communications services and solutions, serving customers in more than 170 countries. Its principal activities include the provision of networked IT services globally; local, national and international telecommunications services to its customers for use at home, at work and on the move; broadband and internet products and services and converged fixed/mobile products and services. BT consists principally of four lines of business: BT Global Services, BT Retail, BT Wholesale and Openreach.
In the year ended 31 March 2012, BT Groups revenue was £18,897m with profit before taxation of £2,445m.
British Telecommunications plc (BT) is a wholly-owned subsidiary of BT Group plc and encompasses virtually all businesses and assets of the BT Group. BT Group plc is listed on stock exchanges in London and New York.
For more information, visit www.btplc.com
